Pfizer beats revenue estimates, raises profit outlook on cost cuts and strong non-Covid sales

The pharmaceutical giant’s quarterly results also benefitted from a smaller-than-feared drop in sales for its Covid antiviral pill Paxlovid.

Previous post NYCB shares jump after new CEO gives two-year plan for “clear path to profitability”
Next post Yum Brands earnings miss estimates as Pizza Hut, KFC sales disappoint